Literature DB >> 29383736

Pharmacokinetics of cefquinome in healthy and Pasteurella multocida-infected rabbits.

S T Elazab1,2, D E Schrunk3, R W Griffith4, S M Ensley3, G Dell'Anna5, K Mullin5, M G Elsayed2, M S Amer2, S M El-Nabtity6, W H Hsu1.   

Abstract

The pharmacokinetics of cefquinome were studied in healthy and Pasteurella multocida-infected rabbits after a single intramuscular (IM) injection at 2 mg/kg of its sulfate salt. Twelve female New Zealand white rabbits (2.0-2.5 kg) were used; six of them served as controls, and the other six had been infected with P. multocida; the experiments were conducted 1-2 days after nasal inoculation of P. multocida when rabbits showed the signs of respiratory infection. Plasma concentrations of cefquinome were determined using high-performance liquid chromatography. The values of elimination half-life, area under the curve, area under the first moment curve, and mean residence time were significantly lower in infected rabbits (0.48 hr, 4.54 hr*μg/ml, 3.63 hr* hr*μg/ml and 0.8 hr, respectively) than healthy rabbits (0.72 hr, 9.11 hr*μg/ml, 9.85 hr* hr*μg/ml and 1.1 hr, respectively), whereas total body clearance was significantly higher in infected than healthy rabbits. Therefore, P. multocida infection caused significant changes in some of the pharmacokinetic parameters of cefquinome in rabbits. These pharmacokinetic changes may affect dose regimen when used in P. multocida-infected rabbits.
© 2018 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29383736     DOI: 10.1111/jvp.12489

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  5 in total

1.  Evaluation of a Pasteurella multocida Respiratory Disease Induction Model for Goats (Capra aegagrus hircus).

Authors:  Joe S Smith; Jonathan P Mochel; Yeon-Jung Seo; Amanda P Ahrens; Ronald W Griffith
Journal:  Comp Med       Date:  2020-09-09       Impact factor: 0.982

2.  Cefquinome Sulfate Oily Nanosuspension Designed for Improving its Bioavailability in the Treatment of Veterinary Infections.

Authors:  Yujuan Mao; Yumeng Chen; Chang Liu; Xingyue He; Yi Zheng; Xiaolan Chen; Ying Wang; Wei Chen; Yanling Wu; Yan Shen; Haifeng Yang; Songbo Ma
Journal:  Int J Nanomedicine       Date:  2022-06-02

3.  Optimal Regimens and Cutoff Evaluation of Tildipirosin Against Pasteurella multocida.

Authors:  Zhixin Lei; Qianying Liu; Yi Qi; Bing Yang; Haseeb Khaliq; Jincheng Xiong; Gopi Krishna Moku; Saeed Ahmed; Kun Li; Hui Zhang; Wenqiu Zhang; Jiyue Cao; Qigai He
Journal:  Front Pharmacol       Date:  2018-07-26       Impact factor: 5.810

4.  In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks.

Authors:  Xia Xiao; Weixuan Lan; Yaqin Zhao; Ruichao Li; Yuan Liu; Juan Liu; Zhiqiang Wang
Journal:  Front Microbiol       Date:  2021-01-11       Impact factor: 5.640

5.  Optimization and Validation of Dosage Regimen for Ceftiofur against Pasteurella multocida in Swine by Physiological Based Pharmacokinetic-Pharmacodynamic Model.

Authors:  Kun Mi; Shanju Pu; Yixuan Hou; Lei Sun; Kaixiang Zhou; Wenjin Ma; Xiangyue Xu; Meixia Huo; Zhenli Liu; Changqing Xie; Wei Qu; Lingli Huang
Journal:  Int J Mol Sci       Date:  2022-03-28       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.